International Web-based consultation on priorities for translational breast cancer research.
about
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialAmplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancerMultigene assays and molecular markers in breast cancer: systematic review of health economic analysesPooling breast cancer datasets has a synergetic effect on classification performance and improves signature stabilityCo-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice.In vivo MRI of early stage mammary cancers and the normal mouse mammary glandMeasuring the performance of markers for guiding treatment decisionsGene signatures of breast cancer progression and metastasis.Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.EPMA position paper in cancer: current overview and future perspectives.The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding TreatmentDesigning a study to evaluate the benefit of a biomarker for selecting patient treatment.Evaluating the efficacy of current clinical practice of adjuvant chemotherapy in postmenopausal women with early-stage, estrogen or progesterone receptor-positive, one-to-three positive axillary lymph node, breast cancer.The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.Linking autophagy with inflammation through IRF1 signaling in ER+ breast cancerThe utility of conventional and molecular pathology in managing breast cancer.Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancerGrading breast cancer tissues using molecular portraits.National Institutes of Health State-of-the-Science Conference on the Management and Diagnosis of Ductal Carcinoma in Situ: a call to action.Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy.Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.The predictive value of epidermal growth factor receptor expression for sensitivity to vinorelbine in breast cancer.Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.Breast cancer screening utilization and understanding of current guidelines among rural U.S. women with private insurance.Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay.Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer.Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.Public Opinions Toward Diseases: Infodemiological Study on News Media Data.
P2860
Q24597456-B6C69041-913B-4815-ABA0-F732E43CE6BCQ24644185-1E240D88-D970-45D7-86C2-CF9E5C9D41B1Q26825362-8DF26A52-A3CD-4BBF-8E62-DE0E959BDE79Q33358309-F936A824-F061-4F0F-8A24-234F0139EAECQ33523022-6BDB09C9-F248-4C69-90E0-92E12E60C047Q33843830-B7792631-1289-4B41-BE7C-F1B022782CDFQ34338152-D2E4A792-2399-434E-8350-402072F3440DQ34395225-467479B2-7F6E-40C4-A0F1-9D50A28C4726Q34610711-3D0075DC-6E0E-4312-8EC9-62C9858B74DDQ34897226-2E64CEA8-3051-4F36-94C9-3C2F9CC0EFC9Q35029477-4ADBE0C7-A8BF-47F0-B442-DEA0C34504DCQ35230269-49D68913-09CA-47BE-BB04-1AB01BE5D84CQ35450768-D7C4276E-BE60-4FB1-98C6-689FFBB12EDCQ35532215-8D92D3C5-76B8-4A39-9912-A903D5FBB3CAQ36173510-C026BEBD-DCCA-4CFE-8190-3C8E96441156Q36225623-81D1A786-FF63-4683-A222-3075ADB548F4Q36278585-E21E0B64-DDEE-4D53-8055-5A514B98A018Q36732425-0F99CA76-725B-4969-BA82-2FDEAB0FF63FQ36836130-0AA5E1E1-4118-4FBB-B806-4A247EAAF73EQ37039845-17454160-85C9-4CAC-B6C8-EF37E774E0A9Q37072811-EB0F3BE2-861C-4A79-9503-0B2998733CE4Q37388984-1EC78821-A995-4141-8038-B9F97ACCD10AQ37509603-64F8A739-28E6-414A-8C5B-B13332F98AE2Q37591446-5531C043-EF49-4E49-908F-7662D7D1D867Q37863628-E5C93132-B95B-4FF1-ACB2-5FE19CBFE5DEQ38395672-42542427-D3BA-415C-8C44-97D380DC789CQ39267625-ACFC8F84-95FD-4E69-A434-E50704B758BCQ39510308-B28E262A-38EC-4DFB-98B2-1EEE394A906AQ41075349-108A04EF-7713-4F2E-A04A-1F3AD6121D10Q41342783-5E2687DD-7425-4429-8748-B2ACA2E56086Q41367403-B25E83F5-0609-4245-B834-2854CEC29865Q42590601-0398EEA6-DF6C-4E40-A606-D1BC4A7DBDFCQ47101130-A7206FD3-EE92-4AAB-A22E-A06D58C0AA29Q47706658-7EC7F14A-2958-4D7D-8779-CB2B1E888516Q51905406-8262944D-1D3B-4E18-AC8A-CAB208A3FF70Q53058836-1731E6D0-5604-45F0-9F1D-CCA434A3B993Q53266957-390B6FBF-77E3-4A7B-AB3E-1B219A7034B1Q53386515-EED141F5-6301-42C1-952F-B6A9B9F51C08Q54217808-4B758B01-2A89-4890-A880-3DD5321864C7
P2860
International Web-based consultation on priorities for translational breast cancer research.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
International Web-based consul ...... tional breast cancer research.
@ast
International Web-based consul ...... tional breast cancer research.
@en
type
label
International Web-based consul ...... tional breast cancer research.
@ast
International Web-based consul ...... tional breast cancer research.
@en
prefLabel
International Web-based consul ...... tional breast cancer research.
@ast
International Web-based consul ...... tional breast cancer research.
@en
P2093
P2860
P356
P1476
International Web-based consul ...... tional breast cancer research.
@en
P2093
Aron Goldhirsch
Daniel F Hayes
Hans-Joerg Senn
William Wood
P2860
P2888
P356
10.1186/BCR1798
P577
2007-01-01T00:00:00Z
P5875
P6179
1027421084